Brought to you by 
Proteostasis signs on Biogen Idec to help with Usp14 inhibitor program
03 Feb 2023
Executive Summary
Proteostasis Therapeutics Inc. (developing therapies for orphan and regenerative diseases and cystic fibrosis) and Biogen Idec Inc. have signed a worldwide R&D deal involving therapeutics that inhibit the ubiquitin specific peptidase 14 (Usp14) enzyme, offering a disease-modifying approach to conditions involving toxic protein aggregation.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Proteostasis signs on Biogen Idec to help with Usp14 inhibitor program
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice